Alclofenac

Summary

Alclofenac (CHEMBL94081) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AB06); indicated across 1 condition including rheumatic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M01AB06
• Indications: 1 condition
• Chemistry: 226.65 Da · C11H11ClO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL94081
Name	Alclofenac
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	30951
ChEBI	CHEBI:31183
ATC	M01AB06
Molecular formula	C11H11ClO3
Molecular weight	226.65
InChIKey	ARHWPKZXBHOEEE-UHFFFAOYSA-N

SMILES: C=CCOC1=C(C=C(C=C1)CC(=O)O)Cl

IUPAC name: 2-(3-chloro-4-prop-2-enoxyphenyl)acetic acid

ChEBI definition: An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, non-narcotic analgesic, drug allergen.

Also known as: Alclofenac, Alclofenaco, Allopydin, Epinal, Medifenac, Mervan, MY-101, Neosten, Neoston, Prinalgin, Reufenac, W 7320

Patent coverage: 3,666 distinct patent families (14,349 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,210 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
rheumatic disorder	4	MONDO:0005554	EFO:0005755

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).